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Abstract
Depression is a highly heterogeneous condition, and identifying how symptoms present in
various groups may greatly increase our understanding of its etiology. Importantly, Major
Depressive Disorder is strongly linked with Substance Use Disorders, which may amelio-
rate or exacerbate specific depression symptoms. It is therefore quite plausible that depres-
sion may present with different symptom profiles depending on an individual’s substance
use status. Given these observations, it is important to examine the underlying construct of
depression in groups of substance users compared to non-users. In this study we use a
non-clinical sample to examine the measurement structure of the Beck Depression Inven-
tory (BDI-II) in non-users and frequent-users of various substances. Specifically, measure-
ment invariance was examined across those who do vs. do not use alcohol, nicotine, and
cannabis. Results indicate strict factorial invariance across non-users and frequent-users of
alcohol and cannabis, and metric invariance across non-users and frequent-users of nico-
tine. This implies that the factor structure of the BDI-II is similar across all substance use
groups
Introduction
There is a longstanding debate regarding whether depression is a homogeneous disorder, or
whether it is a collection of inter-related disorders [1,2]. Depressed mood is generally thought
of as the prototypical depressive symptom [3], but variations in the presentation of depressive
symptoms are often reported. For example, decreased anhedonia and increased somatization
are common in older adults with depression [4,5], whereas irritability is often a primary
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component of depression in adolescents and young adults [3,5,6]. In addition, an “externaliz-
ing” or “aggressive” type of depression has been proposed for some males experiencing depres-
sion [7,8]. This debate has been further exacerbated by the notable lack of replicated molecular
genetic findings for Major Depressive Disorder [9], despite significant heritability estimates
from twin studies [10]. If depression is a heterogeneous condition, identifying symptom pre-
sentation in various groups may greatly increase our understanding of its etiology.
Importantly, Major Depressive Disorder (MDD) is strongly associated with Substance Use
Disorders (SUDs) [11,12,13,14]. One potential reason for this association is the self-medication
hypothesis [15,16], whereby individuals use substances in attempt to control or treat their
depression. If substance use ameliorates or exacerbates specific symptoms, then levels of
depression symptoms may differ depending on an individual’s substance use profile. Further-
more, by acting on specific symptoms, substance use may reduce their diagnostic validity, such
that their presence or absence would be random. The specific symptom that was “treated,”
however, would be a function of the type of substances used. In such cases the frequency with
which the symptom is reported would not necessarily differ between individuals with different
substance use profiles, but the item may become less relevant to the underlying construct of
depression.
While there are several methods of assessing depression, the Beck Depression Inventory
(BDI-II) [17] is one of the most frequently used self-report measures, assessing depressive
symptoms across the spectrum from not depressed to severely depressed. Furthermore, the
BDI-II can be self-administered without clinical supervision, and has been shown to have good
psychometric properties, including convergent validity [18,19], internal consistency [17,18,19]
and test-retest reliability [17]. However, little research has examined the psychometric proper-
ties of the BDI-II among persons with varying levels of substance use, especially among non-
clinical or sub-clinical populations.
The psychometric approach known as measurement invariance [20] provides a method to
test whether the properties of a measurement instrument vary across groups. Formally, mea-
surement invariance is “the mathematical equality of corresponding measurement parameters
for a given factorially defined construct (i.e., the loadings and intercepts of a construct’s multi-
ple manifest indicators) across two or more groups” [21] (p 55). Simply put, tests of measure-
ment invariance examine whether an instrument’s items operate the same way in different
groups. If there ismeasurement invariance of the BDI-II, there are no differences in the mea-
surement, function, or meaning of its items as a function of substance use. Alternatively, if
there is a failure of measurement invariance of the BDI-II with respect to substance use status,
then at least one of the items functions differently in substance users relative to non-users. If a
difference is found, the next step is to identify which items function differently. Importantly, if
a failure of measurement invariance is ignored, then comparing means between groups is con-
founded by the fact that different constructs are being measured.
Measurement Invariance can be statistically investigated by fitting a multiple group com-
mon factor model [20]. In this method, confirmatory factor analysis (CFA) is used to estimate
parameters that reflect differences in the latent construct that the items are intended to assess.
The primary parameters of interest include factor loadings (λ), item means (μ) and item residu-
als (δ). Factor loadings indicate change of each item for a 1-unit increase in the latent factor,
with higher scores indicating stronger relationships. Item means indicate the average value for
each item, and item residuals indicate the variance for each item after accounting for the latent
construct. These parameters are jointly considered in the examination of measurement
invariance.
The measurement invariance status of a set of items is usually classified into one of four
types. First is strict factorial invariance (Fig 1A), in which the number of factors is the same
BDI-II Measurement Invariance among Substance Users and Non-Users
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across groups and factor loadings, item means and variances are not significantly different.
Under strict factorial invariance, the mean(s) and variance(s) of the latent factor may be differ-
ent, but the other measurement components are equivalent, implying that the same construct
is being measured in all groups. In this case, mean differences between the groups are solely a
function of differences in the latent factor, and represent true, interpretable differences. For
example, one group may have higher levels of depression, or more variance in depression, but
the underlying factor structure (i.e., factor loadings and residuals) is the same. Note that differ-
ences in factor mean(s) and variance(s) can only be interpreted if the other parameters can be
equated. Thus, investigators should ensure that these parameters are equal before concluding
that mean or variance differences exist (or don’t) between groups. If a researcher ignores mea-
surement non-invariance, they may be comparing proverbial apples and oranges, rather than
how many apples each group has.
The first type of measurement non-invariance, failure of metric invariance (Fig 1B), involves
differences in factor loadings across groups. An example of this is the study by Aggen and col-
leagues [22] which found that fatigue is more characteristic of depression in older adults,
whereas feelings of worthlessness are less characteristic of depression in older females (age x
sex effect). Accordingly, comparing mean levels of depression in groups where there is a failure
of metric invariance is problematic, as the characteristic depression symptomatology of each
group is different.
The second type of measurement non-invariance, failure of configural invariance (Fig 1C),
occurs when the number of latent factors differs across groups, or when the items that load on
the latent factors in one group are not the same in the other group. In an extreme case, it is pos-
sible for one group to have a three-factor solution, and the other group to have a one-factor
solution. Comparison of the three-factor solution to the one-factor solution would typically be
impossible. An exception might occur if one of the factors in the three-factor group was invari-
ant to the factor in the single-factor group, but such an occurrence is likely quite rare. In fail-
ures of both metric and configural invariance, the underlying constructs differ, making group
mean or variance comparisons prone to error.
Measurement Invariance of the BDI-II in Substance Use Groups
To date, five studies have focused on identifying the factor structure of the BDI-II among sub-
stance use groups [23,24,25,26,27]. In the four that examined the factor structure of the BDI-II
in substance users, a three-factor model consisting of cognitive, affective, and somatic con-
structs appears to fit the data best [23,25,26,27]. In addition, when comparing people with and
without alcohol abuse, Skule et al. [24] found this same three-factor model was the best fitting
solution for both groups.
We are aware of two studies that have examined measurement invariance of the BDI-II
among those with and without SUDs; both found measurement invariance [23,24]. In a recent
study of 525 clinically depressed individuals, Skule and colleagues [24] found support for mea-
surement invariance of the BDI-II across those with and without alcohol abuse. Seignourel,
Green & Schmitz [23] also found support for measurement invariance of the BDI-II across sub-
stance dependence classes (alcohol, opioid and cocaine). However, to our knowledge, no study
Fig 1. Types of Measurement Invariance. Types of measurement invariance, with parameters unable to be
equated displayed in red and dashed. (A) Strict factorial invariance, with between group differences arising
from different factor means and/or different factor variances. (B) Failure of metric invariance, with between
group differences arising from different factor loadings. (C) Failure of configural invariance, with between
group differences arising from different numbers of latent factors.
doi:10.1371/journal.pone.0152118.g001
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to date has examined measurement invariance in sub-clinical substance users, nor in nicotine
or cannabis use groups.
Study Aims / Hypotheses
The aims of the current study were two-fold. First, as the existing literature suggests that sub-
stance abusers have higher levels of depression, our first aim was to replicate this finding in a
non-clinical substance use sample by assessing mean differences in depression symptomatol-
ogy across non-users and frequent-users of alcohol, nicotine and cannabis. Second, we sought
to assess the measurement structure of the BDI-II across these groups to determine if the
BDI-II has the same fundamental meaning for each group. While support for measurement
invariance of the BDI-II has been found across alcohol abusers and non-abusers [24], no one
has yet examined this topic in non-clinical alcohol use groups, nor in any sample involving nic-
otine or cannabis use. Thus, our second aim was to replicate the finding of measurement
invariance of the BDI-II in a non-clinical alcohol use sample, as well as explore the possibility
of supporting measurement invariance in nicotine and cannabis use groups.
Hypothesis A (HA): BDI-II item response means differ significantly between non-users and
frequent-users of each substance. Null hypothesis A (H0A): BDI-II item response means do not
differ significantly between groups.
Hypothesis B (HB): BDI-II factor loadings do not differ significantly between non-users and
frequent-users of each substance (measurement invariance). Null hypothesis B (H0B): BDI-II
factor loadings differ significantly between groups (measurement non-invariance).
Materials and Methods
Participants
Participants were recruited through Amazon’s Mechanical Turk website (MTurk.com) as part
of a larger study on substance use and psychopathology. Previous research has shown MTurk
to be a reliable method of data collection, with Cronbach alphas and test-retest reliability meet-
ing or exceeding other methods of data collection [28]. In total, 603 United States residents
completed the study, with a mean age of 33.3 years (range = 18.5–71.2). The majority of partic-
ipants were female (54.6%) and Caucasian (78.3%). The institutional review board of Virginia
Commonwealth University provided ethical approval for this research, and written informed
consent was obtained from all participants.
Measures
Participants were administered extended questionnaires to assess a variety of traits. To decrease
participant burden and maximize the breadth of the study, a planned missing data strategy was
used, in which participants responded to a random set of questionnaire items. Accordingly, not
all participants answered all questions, but data are missing completely at random and there-
fore the parameter estimates are unbiased [29]. Only participants who completed both the
BDI-II and substance use items (N = 282) are included in the current analyses.
Beck Depression Inventory, Second Edition (BDI-II). The BDI-II [17] is a self-report
measure of depression consisting of 21 items. Each item is rated on a 4-point Likert scale, with
higher scores representing greater severity of depression. In the current study, the item assess-
ing suicidal thoughts was not administered to participants due to concerns by the IRB about
the assessment of suicidality in an online survey, resulting in a total of 20 administered BDI-II
items. S1 Table provides a list of response options for each BDI-II item assessed in the current
study.
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Substance Use Measures. In order to capture reasonably frequent substance use, which
does not necessarily mean abuse or dependence, we compared substance non-users to fre-
quent-users. Due to the non-clinical nature of our sample, as well as the high percentage of
substance non-users (approximately 37% for alcohol, 77% for nicotine and 70% for cannabis),
we chose cut-offs for frequent substance use that would maximize group differences while
maintaining reasonable sample sizes. Substance use categorizations were made based on self-
report, which is the most widely used method to assess substance use, and is generally regarded
as a valid measurement technique for these phenotypes [30,31,32]. Table 1 displays sample
characteristics stratified by substance use category. Specific categorizations for each substance
are presented below.
Participants were assigned to one of two alcohol use groups based on their responses to two
questions: “have you ever had an alcoholic drink?” and “how many drinks do you have in a typ-
ical week?” If participants indicated that they had ever consumed an alcohol drink, then they
were asked to indicate how many drinks they consume in a typical week: 0 drinks, 1 to 3 drinks,
4 to 6 drinks, 7 to 12 drinks, 13 to 18 drinks, 19 to 24 drinks, 25 to 42 drinks, or more than 42
drinks. Participants who endorsed either never having consumed an alcoholic drink, or con-
suming 0 drinks in a typical week were assigned to the alcohol non-user group (N = 105, 37.2%
of the sample). Frequent alcohol users were defined as participants who consumed 4 or more
drinks in a typical week (N = 85, 30.1% of the sample). Occasional drinkers, or participants
who endorsed consuming between 1 and 3 drinks a week were excluded from the analyses. S1
and S2 Figs display the BDI-II item distributions for alcohol non-users and frequent-users,
respectively.
Respondents were assigned to one of two nicotine use groups based on their responses to
two questions. In the first question, participants were asked “what category best describes your
tobacco use history?” Response options included “never smoked or used smokeless tobacco,”
“smoked or used smokeless tobacco on and off,” “use to use tobacco but quit,” and “currently
Table 1. Sociodemographic characteristics and Beck Depression Inventory means for non-users and frequent-users of alcohol, nicotine and can-
nabis. Total and stratified by substance use group.
Alcohol Nicotine Cannabis Total
Non-Users
N (%)
Frequent-Users
N (%)
Non-Users
N (%)
Frequent-Users
N (%)
Non-Users
N (%)
Frequent-Users
N (%)
N (%)
Total N 105 (37.2) 85 (30.1) 218 (77.3) 49 (17.4) 196 (69.5) 62 (22.0) 282
(100.0)
Gender
Male 45 (42.9) 46 (54.1) 111 (51.4) 17 (34.7) 83 (42.6) 34 (55.7) 134 (47.9)
Female 60 (57.1) 39 (45.9) 105 (48.6) 32 (65.3) 112 (57.4) 27 (44.3) 146 (52.1)
Race
White 84 (80.0) 74 (87.0) 176 (81.1) 45 (91.8) 159 (81.1) 51 (83.6) 228 (81.1)
Black 10 (9.5) 5 (5.9) 20 (9.2) 2 (4.1) 17 (8.7) 4 (6.6) 23 (8.2)
Asian 5 (4.8) 4 (4.7) 7 (3.2) 2 (4.1) 9 (4.6) 3 (4.9) 13 (4.6)
Hispanic 4 (3.8) 2 (2.4) 9 (4.1) 0 (0.0) 8 (4.1) 2 (3.3) 12 (4.3)
Other 2 (1.9) 0 (0.0) 5 (2.3) 0 (0.0) 3 (1.5) 1 (1.6) 5 (1.8)
Age
Age [Mean
(SD)]
33.9 (11.9) 32.6 (9.8) 32.4 (10.4) 36.1 (11.1) 33.6 (10.9) 31.6 (9.9) 33.0
(10.5)
BDI-II
Score [Mean
(SD)]
29.5 (10.6) 29.5 (11.2) 28.9 (10.0) 30.9 (11.8) 29.2 (10.5) 29.7 (11.2) 29.5
(10.6)
doi:10.1371/journal.pone.0152118.t001
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smoke or use smokeless tobacco.” Among those who endorsed currently using tobacco, a sec-
ond question was asked: “how frequently did you smoke cigarettes in the last 30 days?”
Response options included 0 days, 1 to 2 days, 3 to 4 days, 5 to 11 days, 12 to 14 days, 15 to 25
days, and 26 to 30 days. Participants who endorsed either never using tobacco, having quit
using tobacco previously, or smoking 0 cigarettes in the last 30 days were assigned to the nico-
tine non-user group (N = 218, 77.3% of the sample). Participants who endorsed smoking ciga-
rettes 15 or more days during the last 30 days were assigned to the nicotine frequent-user
group (N = 49, 17.4% of the sample). Very few participants (less than 6%) endorsed smoking
between 1 and 14 cigarettes in the last 30 days, and these individuals were excluded from the
analyses. S3 & S4 Figs display the BDI-II item distributions for nicotine non-users and fre-
quent-users, respectively.
Respondents were assigned to one of two cannabis use groups based on their response to
two questions: “on how many occasions (if any) have you used marijuana (weed, pot, cannabis)
or hashish (hash, hash oil) in your lifetime?” and “on how many occasions (if any) have you
used marijuana (weed, pot, cannabis) or hashish (hash, hash oil) in the last 12 months?” Only
participants who endorsed using cannabis in their lifetime were asked about their past
12-month use. Response options for both questions were 0 times, 1 to 2 times, 3 to 5 times, 6 to
9 times, 10 to 19 times, 20 to 39 times, and 40 or more times. Participants who endorsed either
never using cannabis, or using cannabis 0 times in the last 12 months were assigned to the can-
nabis non-user group (N = 196, 69.5% of the sample). Participants who endorsed using canna-
bis 3 or more times in the last 12 months were assigned to the cannabis frequent-user group
(N = 62, 22% of the sample). Those who endorsed using cannabis 1 to 2 times in the previous
12 months were excluded from the analyses. S5 & S6 Figs display the BDI-II item distributions
for cannabis non-users and frequent-users, respectively.
Statistical Analysis
To determine the number of BDI-II factors that would be retained for each substance use
group, a polychoric correlation matrix was estimated between the ordinal items, and the eigen-
values of this matrix were computed. Parallel analysis [33] using 1,000 permutations of the
ordinal data was examined and the 97.5% eigenvalue quantile threshold was determined. Origi-
nal eigenvalues that exceeded this threshold were retained in subsequent analyses. For each
group, only a single factor exceeded the parallel analysis threshold, and thus only a single factor
was retained for each group. S7 Fig presents the eigenvalue scree plots [34] for each group,
with Kaiser rule [35] threshold (eigenvalue> 1) displayed in red, and parallel analysis [33]
threshold displayed in blue.
To test for differences in depression symptom levels across groups, we examined a series of
difference of means tests for ordinal variables, in which the first two thresholds were con-
strained to zero and one, respectively, and the third threshold was freely estimated for each
group. These constraints allow for the estimation of the mean and variances of the items,
assuming the liability-threshold model, making these tests analogous to t-tests for continuous
variables [36].
To test for measurement invariance in the BDI-II we examined a series of three nested
structural equation models for each substance use group comparison (alcohol, nicotine and
cannabis). As with the difference of means tests, we used a threshold model in order to account
for the ordinal nature of the BDI-II items. Because there was evidence for a single depression
factor across non-users and frequent-users of each substance (configural invariance), Model 1
served as our base model by specifying the single-factor model and allowing factor loadings to
be freely estimated for each group. Model 2 examined failure of metric invariance by equating
BDI-II Measurement Invariance among Substance Users and Non-Users
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factor loadings across groups. Model 3 assessed strict factorial invariance by equating all
parameters and then freeing the factor means and factor variance. Likelihood ratio tests were
used to examine model fit and determine the best fitting model for each substance. A signifi-
cant deterioration in fit for any of these models indicates a failure of measurement invariance
at that respective level. These procedures were repeated for all three substances (alcohol, nico-
tine and cannabis), comparing non-users to frequent-users.
Parallel analyses and ordinal difference of means tests were performed in OpenMx 2.0 [37]
using the R software package [38]. Measurement invariance models were performed in MPlus
version 6.11 [39].
Results
First, we tested differential levels of BDI-II item-level depression symptomatology by running
a series of ordinal difference of means tests. Following Mehta, Neale & Flay [36], in these tests
the first two thresholds were constrained to zero and one, respectively, and the third threshold
was freely estimated for the non-users and frequent-users for each substance (alcohol, nicotine
& cannabis). These threshold constraints permit estimation of the mean and variance of the
underlying item dimension. Table 2 presents the χ2 statistic and p-value for each BDI-II item
for the ordinal difference of means tests.
For alcohol non-users and frequent-users, there were no significant differences in the
reported means of item-level BDI-II depression symptomatology. For nicotine, feelings of guilt
(item 5) and changes in appetite (item 17) were significantly higher in the frequent-user group
Table 2. Likelihood ratio tests (χ2 and p-value) for ordinal difference of means tests for Beck Depression Inventory items between non-users and
frequent-users of alcohol, nicotine and cannabis.*
Item Alcohol Nicotine Cannabis
χ2 p χ2 p χ2 p
1 < 0.001 .984 1.303 .254 0.549 .459
2 0.678 .410 0.208 .649 0.253 .615
3 0.127 .722 1.637 .201 6.366 .012
4 0.343 .558 2.493 .114 1.852 .174
5 0.459 .498 7.767 .005 0.700 .403
6 0.384 .536 3.234 .072 0.284 .594
7 3.496 .062 0.325 .569 2.910 .088
8 0.299 .584 0.728 .393 0.417 .519
9 2.032 .154 0.365 .545 0.099 .753
10 0.970 .325 1.056 .304 0.240 .624
11 2.517 .113 2.321 .128 < 0.001 .996
12 0.301 .583 1.515 .218 1.011 .315
13 0.223 .637 0.663 .415 0.316 .574
14 0.108 .743 0.060 .807 0.008 .927
15 0.009 .925 0.189 .664 3.314 .069
16 0.200 .655 0.107 .743 0.345 .557
17 0.823 .364 4.175 .041 0.626 .429
18 0.039 .843 0.683 .409 0.211 .646
19 1.903 .168 2.016 .156 < 0.001 1.00
20 2.016 .156 0.181 .671 7.706 .054
* Bold indicates a signiﬁcant difference of means test at α = .05
doi:10.1371/journal.pone.0152118.t002
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than in the non-user group. For cannabis, feelings of failure (item 3) were significantly higher
in the frequent-user group than in the non-user group. Overall, the average level of BDI-II
depression item endorsement appears quite similar for non-users and frequent-users of alco-
hol, nicotine, and cannabis. Although three items did show significant differences across
groups, none of these differences would remain significant after Bonferroni multiple testing
correction. Thus, H0A was not clearly rejected for any of the three substances.
Table 3 presents the goodness-of-fit statistics for the measurement invariance models tested
in each substance category. For these models, a significant difference in likelihood ratio tests
indicates a significant deterioration in model fit, and thus suggests a failure of measurement
invariance. For alcohol and cannabis, the strict factorial invariance model did not significantly
deteriorate model fit, indicating that all model parameters could be equated across non-users
and frequent-users of both alcohol and cannabis. In other words, the measurement structure
for the BDI-II does not appear to be significantly different across non-users and frequent-users
of alcohol and cannabis. For nicotine, the metric invariance model did not significantly deterio-
rate model fit, indicating that the factor loadings could be equated across non-users and fre-
quent-users of nicotine. However, the significant deterioration in fit for the nicotine strict
factorial invariance model indicates that item thresholds were unable to be equated across nico-
tine use groups. In other words, the factor structure of the BDI-II does not appear significantly
different across non-users and frequent-users of nicotine, but the proportion of people in each
response category is significantly different (analogous to different item means and residual var-
iances for continuous variables). Thus, we failed to reject H0B for all three substances. Table 4
presents the factor loading estimates for non-users and frequent-users of each substance under
the factorial invariance models.
Discussion
Our results indicate that a single-factor structure fit the data of the current sample best, with all
items loading onto a single latent construct. Item-level depression symptomatology, as mea-
sured by the BDI-II, did not differ significantly across non-users and frequent-users of alcohol,
nicotine or cannabis. Moreover, the measurement structure of the BDI-II is not significantly
different for non-users and frequent users of alcohol, nicotine and cannabis.
Given that previous research on the factor and measurement structure of the BDI-II has
generally used clinically ascertained samples [23,24,25] our study provides an important exten-
sion to the depression literature by examining the BDI-II structure in a non-clinical sample
using sub-clinical depression and substance use measures. Specifically, we were able to replicate
the previous the findings of measurement invariance in clinical alcohol use samples in a non-
Table 3. Measurement invariancemodel goodness-of-fit statistics for non-users and frequent-users of alcohol, nicotine and cannabis.
Model Estimated Parameters CFI RMSEA χ2 Δdf p
Alcohol non-users vs. frequent-users Conﬁgural Invariance 140 0.985 0.042 - - -
Metric Invariance 120 0.997 0.017 17.242 20 0.6372
Factorial Invariance 82 0.988 0.035 57.661 58 0.4879
Nicotine non-users vs. frequent-users Conﬁgural Invariance 140 0.991 0.030 - - -
Metric Invariance 120 0.992 0.028 26.385 20 0.1535
Factorial Invariance 82 0.985 0.037 88.655 58 0.0059
Cannabis non-users vs. frequent-users Conﬁgural Invariance 138 0.981 0.047 - - -
Metric Invariance 118 0.994 0.026 15.218 20 0.7638
Factorial Invariance 78 0.994 0.023 52.745 60 0.7355
doi:10.1371/journal.pone.0152118.t003
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clinical, sub-threshold sample. Our study also extends the limited research on the BDI-II in
users of nicotine and cannabis by examining the measurement structure of the BDI-II in users
of these substances for the first time.
The current results should be interpreted in light of four potential limitations. First, we were
unable to include the BDI-II item that assesses suicidal ideation, which could display significant
differences across substance use groups. Second, study participants were not provided guide-
lines for reporting alcohol consumption (e.g., portion size and alcohol content), which could
complicate the measurement of alcohol consumption in the current study. Third, our sample
sizes were relatively small (between n = 49 and n = 218 per group), making it more difficult to
reject null hypotheses. Finally, due to the use of a single sample, a poly-substance user could be
included in all three analyses as a frequent-user. Conversely, a total abstainer from all three
substances would be included as a non-user in all analyses. In an ideal scenario the samples
would be independent, making it impossible for an individual to be in the control group (or
frequent-user group) for more than one substance use category. However, inspection of the
data revealed that the frequency of poly-users (defined as frequent-users of all three sub-
stances) and total abstainers (defined as non-users for all three substances) was relatively low
(n = 13 and n = 71; ~ 5% and ~ 25% of the total sample, respectively). Accordingly, the major-
ity of the sample (~70%) was a non-user of one substance and a frequent-user of another
substance.
The current results, especially the nicotine and cannabis use analyses, require replication
before firm conclusions can be drawn. Replication with larger samples, as well as using other
measures of depression is encouraged.
Table 4. Factor loading (λ) estimates for Beck Depression Inventory items for non-users and frequent-users of alcohol, nicotine, and cannabis,
under the factorial invariancemodel.
Parameter Alcohol non-users and frequent users Nicotine non-users and frequent users Cannabis non-users and frequent users
Estimate (SE) Estimate (SE) Estimate (SE)
λ1 0.810 (.046) 0.772 (.046) 0.781 (.037)
λ2 0.661 (.058) 0.713 (.050) 0.705 (.043)
λ3 0.761 (.047) 0.765 (.050) 0.773 (.036)
λ4 0.782 (.045) 0.777 (.047) 0.760 (.034)
λ5 0.837 (.043) 0.829 (.037) 0.795 (.033)
λ6 0.810 (.043) 0.850 (.037) 0.774 (.035)
λ7 0.726 (.052) 0.743 (.050) 0.746 (.038)
λ8 0.844 (.036) 0.879 (.038) 0.825 (.027)
λ9 0.784 (.046) 0.767 (.051) 0.740 (.041)
λ10 0.830 (.041) 0.801 (.047) 0.816 (.032)
λ11 0.870 (.036) 0.832 (.041) 0.781 (.038)
λ12 0.755 (.048) 0.761 (.046) 0.770 (.034)
λ13 0.707 (.047) 0.794 (.044) 0.769 (.036)
λ14 0.809 (.042) 0.800 (.047) 0.788 (.037)
λ15 0.853 (.043) 0.819 (.043) 0.788 (.037)
λ16 0.848 (.036) 0.798 (.047) 0.800 (.035)
λ17 0.760 (.043) 0.806 (.043) 0.759 (.041)
λ18 0.812 (.042) 0.830 (.040) 0.826 (.033)
λ19 0.847 (.041) 0.857 (.041) 0.810 (.034)
λ20 0.811 (.038) 0.809 (.042) 0.797 (.029)
doi:10.1371/journal.pone.0152118.t004
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Conclusions
Our results provide further support for the use of the BDI-II, specifically among substance-
using populations. The BDI-II appears to measure the same construct in both non-users and
frequent-users of alcohol, nicotine and cannabis. Interestingly, no item level mean differences
in depression symptomatology were found between non-users and frequent-users of any sub-
stance, suggesting that symptom-specific levels of depression are approximately equal among
substance use groups. We encourage future research on mean level differences in depression
symptomatology in sub-clinical substance-users.
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